Seres Therapeutics
Seres Therapeutics reported revenue of $1 million in fiscal 2025. Its operating margin was −11,910.1%. Free cash flow was $1 million. The diluted share count rose 14.2%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity. Market cap is the last closing share price times the latest diluted share count, so it is approximate. P/E is the last close divided by diluted earnings per share over the last four quarters, or the latest fiscal year where the quarters aren't available; there is none when the company made a loss.
Charts show fiscal years, from the 10-K filings.
Income statement
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 291 | 181 | 128 | 31 | 46 |
| Debt incl. finance leases | 24 | 50 | 110 | 0 | 0 |
| Net debt (negative means net cash) | −267 | −131 | −18 | −31 | −46 |
| Net debt to EBITDA | — | — | — | — | — |
| Debt to equity | 0.2x | — | — | 0.0x | 0.0x |
| Interest coverage | −22.2x | −29.9x | −79.0x | — | — |
| Current ratio | 3.7x | 2.3x | 1.8x | 0.9x | 2.6x |
| Quick ratio | 3.7x | 2.3x | 1.5x | — | 2.6x |
Cash flow
Projections
Project Seres Therapeutics' revenue, net income and earnings per share five years ahead in a bull, a base and a bear case with your own figures, and see the share prices your P/E estimates give them, or value it with a discounted cash flow model. Every projected figure is yours: it is not a forecast of ours.
Insider trades
Over the 12 months between November 20, 2025 and November 19, 2026, no insider bought Seres Therapeutics shares on the open market, and 5 insiders sold $10,043, $9,599 of it under trading plans set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 17, 2026 | Eric D. ShaffDirector | Sold plan | 263 | $4.55 | $1,197 | Form 4 |
| Aug 17, 2026 | Thomas DesRosierSee Remarks | Sold plan | 82 | $4.55 | $373 | Form 4 |
| Aug 17, 2026 | Matthew R HennSee Remarks | Sold plan | 81 | $4.55 | $369 | Form 4 |
| Aug 17, 2026 | Kelly BradySee Remarks | Sold plan | 64 | $4.55 | $291 | Form 4 |
| May 18, 2026 | Eric D. ShaffDirector | Sold plan | 259 | $7.53 | $1,950 | Form 4 |
| May 18, 2026 | Thomas DesRosierSee Remarks | Sold plan | 79 | $7.53 | $595 | Form 4 |
| May 18, 2026 | Matthew R HennSee Remarks | Sold plan | 77 | $7.53 | $580 | Form 4 |
| May 18, 2026 | Kelly BradySee Remarks | Sold | 59 | $7.53 | $444 | Form 4 |
| Feb 15, 2026 | Eric D. ShaffDirector | Sold plan | 259 | $8.47 | $2,194 | Form 4 |
| Feb 15, 2026 | Matthew R HennSee Remarks | Sold plan | 89 | $8.47 | $754 | Form 4 |
| Feb 15, 2026 | Thomas DesRosierSee Remarks | Sold plan | 78 | $8.47 | $661 | Form 4 |
| Feb 15, 2026 | Teresa L. YoungSee Remarks | Sold plan | 75 | $8.47 | $635 | Form 4 |
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 1 of 8 | 3 of 8 | 5 of 8 |
| Rule of 40 | — | — | — |
| Altman Z'' | −11.26 | −28.64 | −25.59 |
| Accruals ratio | 1.0% | 59.7% | 3.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Fail | Pass | Pass |
| Cash from operations is positive | Fail | Fail | Pass |
| Return on assets rose | Pass | Pass | Pass |
| Cash from operations exceeds net income | Fail | Fail | Fail |
| Debt fell relative to assets | Fail | Pass | Fail |
| Current ratio rose | Fail | Fail | Pass |
| Share count didn't rise | Fail | Fail | Fail |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | Fail | Fail | Pass |
| F-score | 1 of 8 | 3 of 8 | 5 of 8 |
Compare
Put Seres Therapeutics side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Seres Therapeutics | FY25 | — | −11,910.1% | 109.6% | — | — | 5 | |
| Rafael Holdings | FY26 | −4.7% | −3,822.5% | −3,431.3% | — | — | — | Compare |
| Lexaria Bioscience | FY25 | 52.0% | −1,683.0% | −1,483.9% | −929.6% | — | 3 | Compare |
| Dare Bioscience | FY25 | 10,429.4% | −1,315.5% | −997.0% | — | — | — | Compare |
| Yarrow Bioscience | FY25 | 13.8% | −5,219.1% | −5,811.2% | — | — | 3 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 22 | 32 | 28 | 34 | 33 | 145 | 7 | 0 | 0 | 1 |
| Revenue growth | — | 47.5% | −11.9% | 22.1% | −3.7% | 336.3% | −95.1% | −100.0% | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Research and development | 82 | 90 | 96 | 80 | 91 | 142 | 110 | 118 | 65 | 49 |
| Operating income | −93 | −91 | −100 | −72 | −88 | −64 | −180 | −195 | −121 | −94 |
| Net income | −92 | −89 | −99 | −70 | −89 | −66 | −250 | −114 | 0 | 6 |
| Diluted EPS (US$) | −46.00 | −44.20 | −48.60 | −24.80 | −22.40 | −14.40 | −46.20 | −17.77 | 0.00 | 0.64 |
| Diluted shares (millions) | 2 | 2 | 2 | 3 | 4 | 5 | 5 | 6 | 8 | 9 |
| Cash flow | ||||||||||
| Cash from operations | 44 | −76 | −63 | −76 | −94 | 7 | −229 | −117 | −149 | 1 |
| Capital expenditure | 22 | 5 | 2 | 1 | 1 | 10 | 10 | 8 | 0 | 0 |
| Free cash flow | 22 | −80 | −65 | −78 | −94 | −3 | −239 | −125 | −149 | 1 |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 15 | 15 |
| Stock-based compensation | 17 | 17 | 17 | 8 | 9 | 20 | 26 | 34 | 21 | 11 |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 230 | 150 | 86 | 95 | 254 | 291 | 181 | 128 | 31 | 46 |
| Debt incl. finance leases | — | — | — | 25 | 25 | 24 | 50 | 110 | 0 | 0 |
| Total assets | 273 | 190 | 120 | 132 | 343 | 355 | 349 | 359 | 140 | 138 |
| Total liabilities | 140 | 129 | 168 | 181 | 168 | 223 | 338 | 404 | 126 | 94 |
| Shareholders' equity | 133 | 61 | −48 | −48 | 175 | 132 | 11 | −45 | 14 | 44 |
| Margins and ratios | ||||||||||
| Gross margin | — | — | — | — | — | — | — | — | — | — |
| Operating margin | −426.5% | −284.7% | −354.8% | −208.3% | −265.3% | −44.5% | −2,524.1% | — | — | −11,910.1% |
| Net margin | −420.7% | −278.4% | −350.0% | −203.7% | −268.3% | −45.2% | −3,509.5% | — | — | 721.9% |
| Free cash flow margin | 103.0% | −249.8% | −229.2% | −224.7% | −283.6% | −2.0% | −3,347.9% | — | — | 109.6% |
| Rule of 40 (growth + FCF margin) | — | −202.4% | −241.2% | −202.6% | −287.4% | 334.3% | −3,443.0% | — | — | — |
| Return on capital | — | — | — | — | — | — | — | — | — | — |
| Return on equity | −54.2% | −92.5% | — | — | −141.0% | −42.8% | −351.6% | — | — | 19.6% |
| Return on assets | −37.4% | −38.7% | −63.8% | −55.6% | −37.5% | −18.8% | −71.1% | −32.1% | 0.1% | 4.1% |
| Net debt to EBITDA | — | — | — | — | — | — | — | — | — | — |